We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Chemotherapy May Paradoxically Trigger Future Cancer

By Biotechdaily staff writers
Posted on 23 May 2002
Research has revealed that some drugs used in chemotherapy may actually cause conditions that can lead to the future growth of a cancerous tumor.

Chemotherapy drugs work by interfering with the ability of cancer cells to divide and reproduce themselves. More...
The affected cells become damaged and eventually die. As the drugs are carried in the blood, they can reach cancer cells all over the body. Chemotherapy has to be carefully planned so that it progressively destroys the cancer during the course of treatment but not the normal cells and tissues.

Prof. Batsheva Kerem of the Hebrew University of Jerusalem (Jerusalem, Israel) and colleagues have been studying the chromosomes in cancer cells. They found that cancer cell chromosomes break recurrently at specific regions known as "fragile sites,” sites where the mechanism responsible for DNA replication is disturbed. This could lead to breakage resulting in multiple rearrangements of the chromosomes, a striking characteristic of cancer cells.

Now the researchers report that normal cells also develop fragile regions when they are exposed to certain conditions. Some of the drugs used in chemotherapy may cause these conditions and thus plant the seeds of a future cancerous growth at the same time they are killing the current one. There are some 100 fragile sites in the human genome and five of these sites are now being studied. These findings were reported in the inaugural edition of Cancer Cell, published February 26, 2002.

The researchers say this work creates a better understanding of how chemotherapy drugs work, which will help guide the development of a new generation of drugs designed to halt the growth of cancer cells without inducing fragile sites in normal cells.




Related Links:
The Hebrew University of Jerusalem

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.